Cargando…

922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas

Detalles Bibliográficos
Autores principales:	Forster, M., Metcalf, R., Sacco, J., Kong, A., Wheeler, G., Forsyth, S., Bhat, R., Blair, K., Ward, J., Lowe, H., Spanswick, V., Ensell, L., Hartley, J., White, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506496/ http://dx.doi.org/10.1016/j.annonc.2020.08.1037

Ejemplares similares

Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK
por: Ng, Kenrick, et al.
Publicado: (2023)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
por: Andric, Zoran, et al.
Publicado: (2023)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
por: Tintelnot, Joseph, et al.
Publicado: (2022)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours
por: Childs, Alexa, et al.
Publicado: (2016)

Myelodysplasia and Mast Cell Leukemia with t(9;22)
por: Lago, Kathryn J., et al.
Publicado: (2017)

Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
por: Fasano, Morena, et al.
Publicado: (2020)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
por: Lonardi, Sara, et al.
Publicado: (2021)

Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples
por: Spanswick, Victoria J, et al.
Publicado: (2012)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

Complex Crystal Structure Determination of Hsp90(N)-NVP-AUY922 and In Vitro Anti-NSCLC Activity of NVP-AUY922
por: He, Chun-Xia, et al.
Publicado: (2022)

POS-922 Psychological Impact of Covid 19 in Hemodialysis Patients
por: ALAFIFI, R., et al.
Publicado: (2022)

Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours
por: Rizzo, Francesca M., et al.
Publicado: (2019)

Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy
por: Li, Si, et al.
Publicado: (2021)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

A review of avelumab in locally advanced and metastatic bladder cancer
por: Rao, Arpit, et al.
Publicado: (2019)

Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma
por: ISHIKAWA, CHIE, et al.
Publicado: (2016)

Efficacy and immune-related adverse event associations in avelumab-treated patients
por: Kelly, Karen, et al.
Publicado: (2020)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
por: Baro, M, et al.
Publicado: (2014)

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
por: Stingl, L, et al.
Publicado: (2010)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2022)

Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours
por: Mellinas-Gomez, Maria, et al.
Publicado: (2015)

Trisomy 19 and T(9;22) In a Patient with Acute Basophilic Leukemia
por: Rojas-Atencio, Alicia, et al.
Publicado: (2011)

SUN-922 An Indolent Recurrent Parathyroid Carcinoma - A Case Report
por: Murthi, Swetha, et al.
Publicado: (2020)

AUY922 induces retinal toxicity through attenuating TRPM1
por: Shen, Che-Hung, et al.
Publicado: (2021)

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020)

Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
por: Dobrzynski, Jeffrey L., et al.
Publicado: (2022)

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer
por: Brown, Landon C., et al.
Publicado: (2022)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival
por: Lohray, Rishabh, et al.
Publicado: (2023)

Re-Induction of Avelumab for Patients with Metastatic Merkel Cell Carcinoma
por: Hiroyuki, Goto, et al.
Publicado: (2023)

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
por: Dudek, A Z, et al.
Publicado: (2009)

Characteristics of hematologic malignancies with coexisting t(9;22) and inv(16) chromosomal abnormalities
por: Han, Eunhee, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_83ukcqcgajpatv943u54satc08